Skeletal muscle responds to a complicated network of molecular signals. Some regulate cell proliferation, others influence differentiation, protein turnover or the development of muscle fibres. The insulin-like growth factor system is one of the signalling networks researchers have studied in this area.
IGF-1 LR3, also known as Long R3 IGF-I, is a modified analogue of insulin-like growth factor 1 (IGF-1). In laboratory research, it has been used to investigate IGF receptor signalling and related processes in skeletal muscle cells.
Rather than viewing IGF-1 LR3 through the lens of “muscle recovery”, it is more useful to look at the questions researchers have actually asked. These include how IGF signalling interacts with Akt and mTOR, what happens during myoblast proliferation and differentiation, and how IGF-binding proteins influence these processes.
There is an important distinction throughout this research. IGF-1 LR3 and naturally occurring IGF-1 are related, but they are not identical molecules. Findings involving one should not automatically be attributed to the other.
What is IGF-1 LR3?
IGF-1 LR3 is a modified IGF-1 analogue used in laboratory research to investigate IGF-1 receptor signalling and related biological pathways.
IGF-1 LR3 is a modified form of IGF-1. Its structure includes an arginine substitution at position three and an additional amino-acid sequence at the N-terminus.
These changes affect the way the molecule interacts with insulin-like growth factor binding proteins, or IGFBPs.
That characteristic is particularly useful in experimental work. Long R3 IGF-I has a much lower affinity for IGFBPs than IGF-I while retaining the ability to interact with the type 1 IGF receptor, IGF-1R.
Researchers can therefore use the analogue when investigating receptor-associated signalling while reducing some of the influence created by IGF-binding proteins.
IGF-1R Signalling in Skeletal Muscle Research
IGF-1R is a transmembrane receptor tyrosine kinase. When an appropriate ligand binds to the receptor, it can initiate several intracellular signalling events.
One pathway frequently investigated in skeletal muscle research involves:
Akt sits within a much larger signalling network. Downstream processes can involve mTOR, TSC2, S6K1 and other proteins associated with cellular growth and protein synthesis.
The pathway is not a simple sequence in which activating one protein guarantees a particular biological outcome. Signalling networks interact with one another, and results can change according to cell type, experimental conditions, differentiation stage and the presence of other regulatory molecules.
This is why laboratory measurements of pathway activity should not be translated into claims about human outcomes.
IGF-1 LR3, FAK and mTOR Signalling
Research by Crossland and colleagues provides a useful example of how Long R3 IGF-I has been used to examine skeletal muscle signalling.
The researchers investigated focal adhesion kinase, usually abbreviated to FAK, and its involvement in IGF-I-associated growth signalling in skeletal muscle cells.
Their experiments included primary human skeletal muscle cells treated with Long R3 IGF-I. The researchers examined several signalling components, including FAK, TSC2, mTOR and S6K1.
Rapamycin was also used in parts of the experiment to inhibit mTOR signalling. Using an inhibitor in this way helps researchers determine whether an observed cellular response depends on a particular part of the pathway.
The study connected FAK with a TSC2/mTOR/S6K1-associated signalling mechanism under the experimental conditions tested.
This tells us something about the molecular machinery involved in IGF-associated skeletal muscle signalling. It does not establish a therapeutic application for IGF-1 LR3 or demonstrate a particular outcome in humans.
What Happens in Myoblast Research?
Myoblast research uses precursor muscle cells to investigate processes such as proliferation, differentiation and the signalling mechanisms involved in skeletal muscle development.
Myoblasts are precursor cells involved in the formation of skeletal muscle fibres. Before mature fibres develop, these cells undergo processes including proliferation, differentiation and fusion.
That makes myoblast cultures useful experimental models.
Pampusch and colleagues investigated porcine embryonic myogenic cells using both IGF-I and Long R3 IGF-I. Their research focused on IGF-binding protein 5, known as IGFBP-5, and its influence on cell proliferation.
Long R3 IGF-I was particularly useful in this experiment because it retains activity at the type 1 IGF receptor while having very low affinity for IGF-binding proteins.
The researchers found that recombinant IGFBP-5 suppressed Long R3 IGF-I-stimulated proliferation even when the analogue was present in substantial molar excess. This helped provide evidence that IGFBP-5 could exert effects that were not dependent solely on conventional IGF binding.
It is a good example of IGF-1 LR3 being used as a research tool to untangle a biological mechanism rather than simply to observe whether cells grow.
IGF-Binding Proteins Add Another Layer
IGF signalling cannot be understood by looking only at IGF-1 and its receptor.
Several IGF-binding proteins regulate the availability and behaviour of IGF molecules. Their involvement can alter what researchers observe in an experimental system.
Further work with porcine embryonic myogenic cells examined IGFBP-3 and IGFBP-5 in relation to transforming growth factor beta (TGF-β) and myostatin.
Researchers used Long R3 IGF-I while investigating how these binding proteins influenced cell proliferation. When both IGFBP-3 and IGFBP-5 were immunoneutralised under certain experimental conditions, Long R3 IGF-I-stimulated DNA synthesis changed substantially.
Experiments such as these illustrate why individual signalling pathways should not be considered in isolation. IGF signalling takes place alongside numerous regulatory proteins that can alter the cellular response.
IGF-1 LR3 and Akt Signalling
Akt is another recurring feature of skeletal muscle research involving Long R3 IGF-I.
A study examining the relationship between myostatin and IGF-associated signalling used differentiated C2C12 myotubes, a mouse skeletal muscle cell model.
Long R3 IGF-I was used as the experimental IGF stimulus. Researchers then examined Akt phosphorylation and changes in myotube diameter while manipulating myostatin signalling.
Under the conditions studied, increased myostatin activity attenuated both the Long R3 IGF-I-associated change in myotube diameter and Akt phosphorylation. Manipulating Akt produced further changes, helping the researchers investigate where Akt fitted into the interaction between the two signalling systems.
The important point is the mechanism. The experiment helped identify an interaction between myostatin and IGF-associated Akt signalling in cultured mouse muscle cells.
It should not be interpreted as evidence for a muscle-building or performance benefit from IGF-1 LR3.
Why Are C2C12 Cells Used?
C2C12 cells provide a controlled laboratory model for studying skeletal muscle cell differentiation, signalling and myotube development.
C2C12 cells appear frequently in skeletal muscle research. They originate from mouse muscle and can differentiate from myoblasts into multinucleated myotubes under suitable laboratory conditions.
This gives researchers a relatively controlled system in which to examine processes such as differentiation, signalling and myotube development.
Long R3 IGF-I has been used in C2C12 experiments investigating several parts of muscle biology.
For example, research into TGF-β signalling found that R3-IGF-I stimulated Akt phosphorylation and altered measures of muscle differentiation under the experimental conditions studied.
These models are useful because individual variables can be manipulated more easily than in an intact biological system. That advantage also creates an obvious limitation. A cultured mouse muscle cell is not equivalent to human skeletal muscle in a living person.
Cell Studies and Animal Models Answer Different Questions
The phrase “research shows” can hide important differences between evidence types.
A cell culture experiment might measure receptor activity or phosphorylation of a signalling protein over minutes or hours. An animal experiment can examine interactions between tissues and biological systems over a longer period.
They answer different questions.
For IGF-1 LR3 research, it is useful to separate the evidence into categories:
- In vitro studies examine cells or tissues outside a living organism. These models allow researchers to control experimental conditions and investigate specific molecular pathways.
- Animal studies add another layer of biological complexity, covering the interactions between tissues and the substances circulating in the blood. They are still considered preclinical models.
- Human research represents a separate evidence category and should not be inferred from either cell or animal findings.
The model used is therefore just as important as the result reported.
IGF-1 LR3 and Native IGF-1 Are Not Interchangeable
This distinction is easy to lose when reading the literature.
There is extensive research into the IGF system, including native IGF-1, recombinant forms of IGF-I and modified analogues. That does not mean every finding belongs under the heading of IGF-1 LR3 research.
When reviewing a paper, researchers should check exactly which molecule was used.
Long R3 IGF-I is often selected experimentally because its reduced affinity for IGFBPs helps researchers investigate particular aspects of IGF receptor biology. A study involving native IGF-1 may still provide useful background on the pathway, but it is not automatically evidence about the LR3 analogue itself.
Keeping those evidence streams separate produces a much clearer picture of what has actually been studied.
What Can the Current Research Tell Us?
Current research uses IGF-1 LR3 to investigate skeletal muscle signalling and cellular processes, with findings primarily limited to experimental models.
Experimental studies show that IGF-1 LR3 has been used to investigate several areas of skeletal muscle biology, including:
- IGF-1 receptor-associated signalling
- Akt pathway activity
- FAK, TSC2, mTOR and S6K1 signalling
- myoblast proliferation
- myogenic differentiation
- interactions involving IGF-binding proteins
- interactions between IGF and myostatin-associated signalling
The strength of this literature is mechanistic. Researchers can manipulate individual parts of a signalling network and observe how cells respond.
Its limitations are equally important.
Cellular activity under controlled experimental conditions does not establish clinical efficacy, safety or suitability for human use. Nor should findings concerning pathway activation be converted into claims about recovery, strength, athletic performance or muscle growth in people.
How Should IGF-1 LR3 Studies Be Read?
The details of an experiment matter.
Before drawing conclusions from an IGF-1 LR3 paper, it helps to ask:
- Was Long R3 IGF-I actually used in the experiment?
- What species or cell line was studied?
- Was the research conducted in vitro or in vivo?
- What endpoint did the researchers measure?
- How long were the cells or tissues exposed?
- Were inhibitors or other signalling compounds present?
- Was the study examining proliferation, differentiation or signalling activity?
- Does the conclusion go beyond what the experimental model can demonstrate?
These checks are particularly useful when research findings have been summarised elsewhere without the original experimental context.
Limitations of Current IGF-1 LR3 Research
Several limitations need to be kept in mind.
Much of the relevant mechanistic research uses isolated cells, cultured muscle models or animals. Results can depend heavily on the model and experimental conditions.
The IGF signalling network itself is also complex. IGF-1R, IGFBPs, Akt, mTOR, myostatin and other signalling components interact rather than operating independently.
Another limitation is the tendency to group different IGF molecules together. Research involving native IGF-1 cannot automatically be used as direct evidence for IGF-1 LR3.
Finally, evidence of biological activity is not evidence of clinical effectiveness. These are separate questions requiring different types of research.
IGF-1 LR3 Skeletal Muscle Research Overview
IGF-1 LR3 has been studied in experimental skeletal muscle models to examine IGF-1R signalling, Akt and mTOR pathways, myoblast behaviour and interactions with IGF-binding proteins. Current findings are largely mechanistic and should not be interpreted as evidence of clinical effects.
IGF-1 LR3 skeletal muscle research FAQs
IGF-1 LR3, also known as Long R3 IGF-I, is a modified analogue of insulin-like growth factor 1. Researchers have used it in skeletal muscle models to investigate IGF-1 receptor signalling, myogenic processes and interactions with IGF-binding proteins. Its reduced affinity for IGF-binding proteins makes it particularly useful in certain experimental settings.
IGF-1 LR3 contains structural modifications that distinguish it from naturally occurring IGF-1. One important difference is its substantially reduced affinity for IGF-binding proteins while retaining interaction with the type 1 IGF receptor. Findings from native IGF-1 studies therefore should not automatically be attributed to IGF-1 LR3.
Experimental research has used Long R3 IGF-I to investigate signalling involving IGF-1R, PI3K/Akt and downstream components associated with mTOR signalling. Studies have also examined proteins such as FAK, TSC2 and S6K1. These findings describe molecular activity under defined experimental conditions rather than clinical outcomes.
Myoblast and myotube models allow researchers to study processes involved in skeletal muscle cell development under controlled conditions. Long R3 IGF-I has been used in these models to examine proliferation, differentiation and intracellular signalling, as well as interactions between the IGF system and other regulatory pathways.
IGF-binding proteins, or IGFBPs, regulate the availability and behaviour of IGF molecules. Because IGF-1 LR3 has much lower affinity for these proteins than native IGF-1, researchers can use the analogue to help investigate which experimental responses involve IGF receptor signalling and which may involve IGFBPs through other mechanisms.
No. Much of the research discussed in this article involves cultured cells, isolated biological systems or preclinical models. Such studies can provide information about molecular mechanisms and signalling pathways, but they do not establish clinical efficacy, safety or suitability for human use.
No. Although IGF-1 LR3 is an analogue of IGF-1, its structural modifications alter characteristics such as its interaction with IGF-binding proteins. Research involving native IGF-1 can provide useful background on the wider IGF system, but direct conclusions about IGF-1 LR3 should be based on studies in which the LR3 analogue was actually investigated.
Scientific references
- 1 Pampusch MS, Xi G, Kamanga-Sollo E, Loseth KJ, Hathaway MR, Dayton WR, White ME. Production of recombinant porcine IGF-binding protein-5 and its effect on proliferation of porcine embryonic myoblast cultures in the presence and absence of IGF-I and Long-R3-IGF-I. J Endocrinol. 2005 Apr;185(1):197-206. doi: 10.1677/joe.1.06037. https://pubmed.ncbi.nlm.nih.gov/15817840/
- 2 Kamanga-Sollo E, Pampusch MS, White ME, Hathaway MR, Dayton WR. Insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5 mediate TGF-beta- and myostatin-induced suppression of proliferation in porcine embryonic myogenic cell cultures. Exp Cell Res. 2005 Nov 15;311(1):167-76. doi: 10.1016/j.yexcr.2005.09.003. Epub 2005 Oct 6. https://pubmed.ncbi.nlm.nih.gov/16214131/
- 3 Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol. 2009 Jun;296(6):C1258-70. doi: 10.1152/ajpcell.00105.2009. Epub 2009 Apr 8. https://pubmed.ncbi.nlm.nih.gov/19357233/
- 4 Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol. 2009 Nov;297(5):C1124-32. doi: 10.1152/ajpcell.00043.2009. Epub 2009 Sep 16. https://pubmed.ncbi.nlm.nih.gov/19759331/
- 5 Crossland H, Kazi AA, Lang CH, Timmons JA, Pierre P, Wilkinson DJ, Smith K, Szewczyk NJ, Atherton PJ. Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway. Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E183-93. doi: 10.1152/ajpendo.00541.2012. Epub 2013 May 21. https://pubmed.ncbi.nlm.nih.gov/23695213/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.